Developing a Standardized Definition for Disease “Flare” in Rheumatoid Arthritis (OMERACT 9 Special Interest Group)
暂无分享,去创建一个
Mahboob Rahman | M. Boers | D. Furst | C. Bingham | C. Pohl | T. Woodworth | R. Alten | S. Hewlett | C. V. Strand | James P Witter | M. U. Rahman | James E. May | J. Witter | Sarah E. Hewlett | Mahboob U. Rahman | James P. Witter | Daniel E. Furst | M. B. C. VIBEKE STRAND | Schlosspark Klinik | Dr. C.O. Bingham | James Witter
[1] A. Martini,et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial , 2008, The Lancet.
[2] P. V. van Riel,et al. Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study , 2008, Annals of the rheumatic diseases.
[3] Y. Goekoop-Ruiterman,et al. Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. , 2007, Arthritis and rheumatism.
[4] J. Hazes,et al. Measuring disease activity and functionality during pregnancy in patients with rheumatoid arthritis. , 2007, Arthritis and rheumatism.
[5] J. Kirwan,et al. Patient perspective: reasons and methods for measuring fatigue in rheumatoid arthritis. , 2007, The Journal of rheumatology.
[6] M. Suarez‐Almazor,et al. Patient perspective: fatigue as a recommended patient centered outcome measure in rheumatoid arthritis. , 2007, The Journal of rheumatology.
[7] Mahboob Rahman,et al. Double-blinded infliximab dose escalation in patients with rheumatoid arthritis , 2007, Annals of the rheumatic diseases.
[8] M. Dougados,et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis , 2006, Annals of the rheumatic diseases.
[9] M. Boers,et al. Assessing single joints in arthritis clinical trials. , 2007, The Journal of rheumatology.
[10] B. Rintelen,et al. Lack of agreement between patients' and physicians' perspectives of rheumatoid arthritis disease activity changes , 2006, Scandinavian journal of rheumatology.
[11] J. Smolen,et al. [Measuring disease activity for rheumatoid arthritis]. , 2006, Zeitschrift fur Rheumatologie.
[12] Mimi Y. Kim,et al. Combined oral contraceptives in women with systemic lupus erythematosus. , 2005, The New England journal of medicine.
[13] M. D. de Wit,et al. Progress since OMERACT 6 on including patient perspective in rheumatoid arthritis outcome assessment. , 2005, The Journal of rheumatology.
[14] J. Kremer,et al. Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trial* , 2005, Current medical research and opinion.
[15] J. Daurès,et al. Practices for managing a flare of long-standing rheumatoid arthritis: survey among French rheumatologists. , 2005, Clinical and experimental rheumatology.
[16] D. Symmons,et al. ICF Core Sets for rheumatoid arthritis. , 2004, Journal of rehabilitation medicine.
[17] C. Gordon,et al. Definition and treatment of lupus flares measured by the BILAG index. , 2003, Rheumatology.
[18] P. Tugwell,et al. MCID/Low Disease Activity State Workshop: low disease activity state in rheumatoid arthritis. , 2003, The Journal of rheumatology.
[19] P. Tugwell,et al. MCID/Low Disease Activity State Workshop: summary, recommendations, and research agenda. , 2003, The Journal of rheumatology.
[20] J. Kirwan,et al. Rheumatology outcomes: the patient's perspective. , 2003, The Journal of rheumatology.
[21] E. Taal,et al. Outcomes from the Patient Perspective Workshop at OMERACT 6. , 2003, The Journal of rheumatology.
[22] D. Erkan,et al. Decreased flares of rheumatoid arthritis during the first year of etanercept treatment: further evidence of clinical effectiveness in the “real world” , 2002, Annals of the rheumatic diseases.
[23] P. V. van Riel,et al. Dose titration using the Disease Activity Score (DAS28) in rheumatoid arthritis patients treated with anti-TNF-alpha. , 2002, Rheumatology.
[24] E. Giannini,et al. Preliminary definition of disease flare in juvenile rheumatoid arthritis. , 2002, The Journal of rheumatology.
[25] G. Stucki,et al. Responsiveness of the self-assessed rheumatoid arthritis disease activity index to a flare of disease activity. , 2001, Arthritis and rheumatism.
[26] Andre Peeters,et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis , 2000 .
[27] A. Silman,et al. Breast-feeding and postpartum relapse in women with rheumatoid and inflammatory arthritis. , 2000, Arthritis and rheumatism.
[28] A. Reiff,et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. , 2000, The New England journal of medicine.
[29] Mimi Y. Kim,et al. Classification and definition of major flares in SLE clinical trials , 1999, Lupus.
[30] D. Furst,et al. Flare during drug withdrawal as a method to support efficacy in rheumatoid arthritis: amiprilose hydrochloride as an example in a double blind, randomized study. , 1998, The Journal of rheumatology.
[31] D. Felson,et al. Preliminary definition of improvement in juvenile arthritis. , 1997, Arthritis and rheumatism.
[32] B. Dijkmans,et al. Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis , 1996, The Lancet.
[33] P. Gøtzsche,et al. Randomized, placebo controlled trial of withdrawal of slow-acting antirheumatic drugs and of observer bias in rheumatoid arthritis. , 1996, Scandinavian journal of rheumatology.
[34] J. Kremer,et al. Severe flare of rheumatoid arthritis after discontinuation of long-term methotrexate therapy. Double-blind study. , 1987, The American journal of medicine.